Medical Marketing Roadmap← All research

ARPA-H put $98.5M behind the idea that rare-disease AI is failing on data plumbing, not on algorithms

September 3, 2026 · 2 items

Medical Marketing Roadmap AI research illustration for September 3, 2026 — AI in independent medical practice

A startup is selling AI models with the safety training surgically removed — and a reporter got malware and a pathogen protocol out of it in minutes

TechCrunch · Rebecca Bellan · September 3, 2026Buildable AI

Why it matters for an independent practice: This is the "who can reach what, and under whose rules" shape that has earned :+1: here twice, and it lands on a comfortable assumption. When a practice buys an AI receptionist, an intake bot, or a content tool, everyone quietly assumes the safety behavior is a property of the model. It isn't — it's a product decision that a third party can remove and resell for the price of a credit card. So the vendor question sharpens: which model, hosted where, and has anyone modified it? A reseller who can't answer that in one sentence hasn't thought about it. The second-order effect is closer to home than the bioweapon headline: uncensored models make convincing patient-facing phishing, fake portal messages and physician impersonation cheaper to produce at volume — the same threat that hit Epic MyChart last week, with the production cost taken out.

A spine institute opened a PRP and adipose-cell center — and the press release is a clinic in how to launch regen without making a claim

Ortho Spine News · Tim Allen · September 3, 2026Regenerative medicine

Why it matters for an independent practice: Every regen client MMR serves has to answer the same question this release answers: how do you announce a cash-pay biologics service without writing the sentence that draws an FDA warning letter or a state board complaint? This is the template. Claims are made about the field's promise, never about the patient's outcome; the physician's quote spends its words on who is not a candidate; and the service is framed as one option inside a diagnostic practice rather than a product being sold. That last move is the strategically interesting one — it makes the offer harder to commoditize and harder to attack, because the thing being sold is the evaluation, not the injection. Worth holding up against any client's current regen page. Most of them fail at the first verb.